美罗培南治疗新生儿脓毒症的临床实践指南(2024年版)OA北大核心CSTPCD
Clinical practice guidelines for meropenem therapy in neonatal sepsis(2024)
美罗培南是新生儿脓毒症治疗中使用最为广泛的特殊级别抗菌药物之一,但其不合理应用导致细菌多重耐药问题日益严峻.该指南遵循规范的制订方法与流程,针对9个临床问题形成了12条推荐意见,内容涵盖新生儿美罗培南的使用时机、推荐剂量、延长输注、监测与评估、抗菌药物调整方案、治疗疗程以及碳青霉烯耐药肠杆菌目细菌感染的治疗策略,以期为美罗培南在新生儿脓毒症患儿中的合理使用提供循证证据与用药建议.[中国当代儿科杂志,2024,26(2):107-117]
Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis.However,its irrational use has led to an increasingly severe problem of bacterial multidrug resistance.The guideline was developed following standardized methods and procedures,and provides 12 recommendations specifically addressing 9 clinical issues.The recommendations cover various aspects of meropenem use in neonates,including timing of administration,recommended dosage,extended infusion,monitoring and assessment,antimicrobial adjustment strategies,treatment duration,and treatment strategies for carbapenem-resistant Enterobacteriaceae infections.The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.[Chinese Journal of Contemporary Pediatrics,2024,26(2):107-117]
《美罗培南治疗新生儿脓毒症的临床实践指南》制订组;北京大学第三医院;《中国当代儿科杂志》编辑部;童笑梅;周文浩;杨克虎
北京大学第三医院儿科国家儿童医学中心/复旦大学附属儿科医院新生儿科兰州大学基础医学院循证医学中心/世界卫生组织指南实施与知识转化合作中心/甘肃省医学指南行业技术中心
美罗培南脓毒症指南新生儿
MeropenemSepsisClinical practice guidelineNeonate
《中国当代儿科杂志》 2024 (002)
107-117 / 11
国家重点研发计划(2021YFC2700700);国家自然科学基金项目(72304008).
评论